Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04056026 · ClinicalTrials.gov registry record · Early Phase 1
A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma
A Early Phase 1 study, sponsored by ProgenaBiome.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT04056026: Completed Early Phase 1 study, sponsored by ProgenaBiome.
NCT04056026 is a Early Phase 1 study that has completed, run by ProgenaBiome. The registered enrollment target is 1 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04056026, a Early Phase 1 study, has completed, sponsored by ProgenaBiome.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The investigators propose to ensure a favorable gut microbiome by fecal microbiota transplant to enhance the efficacy Keytruda
Primary Outcome
The time from transplant that the patient's tumors remain stable or shrink.
Interventions
- BIOLOGICAL Fecal Microbiota Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2018-12-18 |
| Phase | Early Phase 1 |
What the finished NCT04056026 record still lists
NCT04056026 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Fecal Microbiota Transplant is the first listed.
NCT04056026 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04056026 about?
NCT04056026 is a clinical study titled "A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma". The investigators propose to ensure a favorable gut microbiome by fecal microbiota transplant to enhance the efficacy Keytruda
What is the current status of trial NCT04056026?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2018-09-18. Estimated completion is 2018-12-18.
What interventions are being tested in trial NCT04056026?
The interventions under investigation include: Fecal Microbiota Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT04056026?
This trial is sponsored by ProgenaBiome, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04056026's enrollment target sits among peer trials
1 1986th of 2000 the lowest of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI